Ann Lab Med.  2020 Mar;40(2):95-96. 10.3343/alm.2020.40.2.95.

Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine

• Lee SY

• KMID: 2460904
• DOI: http://doi.org/10.3343/alm.2020.40.2.95

Abstract

No abstract available.

MeSH Terms

Biological Factors*
Drug Monitoring*
Precision Medicine*
Biological Factors

Reference

1. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011; 106:685–698.

2. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017; 153:835–857.

3. Choi R, Jeong BH, Koh WJ, Lee SY. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med. 2017; 37:97–107.

4. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019; 17:1655–1668.

5. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019; 15:837–848.

6. Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res. 2019; 17:285–310.

7. Jourdil JF, Nemoz B, Gautier-Veyret E, Romero C, Stanke-Labesque F. Simultaneous quantification of adalimumab and infliximab in human plasma by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2018; 40:417–424.

8. Willeman T, Jourdil JF, Gautier-Veyret E, Bonaz B, Stanke-Labesque F. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. Anal Chim Acta. 2019; 1067:63–70.

9. Benucci M, Grossi V, Manfredi M, Damiani A, Infantino M, Moscato P, et al. Laboratory monitoring of biological therapies in rheumatology: the role of immunogenicity. Ann Lab Med. 2020; 40:101–113.